EU fines Lundbeck, 8 others for generic-delay payments

06/19/2013 | Reuters

Nine drug firms have been given fines by the EU, including Denmark's Lundbeck, Germany's Merck and India's Ranbaxy, totaling $195 million for payments to delay the release of lower-priced generic versions of brand-name drugs, or "pay for delay" schemes. "Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints," said EU Competition Commissioner Joaquin Almunia. Lundbeck and Ranbaxy have said they will appeal.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD